Targeting CD38/CD3 in the immunotherapy of Multiple Myeloma
Multiple myeloma is a common hematological malignancy that has its origins in plasma cells. Despite treatment becoming more sophisticated, there is still currently no cure. However, immunotherapy targeting CD38/CD3 is proving to be very promising.
Source: news-medical.net